摘要
目的：观察卡维地洛和比索洛尔对慢性心力衰竭患者血浆脑钠肽(BNP)水平及左心室收缩功能的变化。方法：79例慢性心力衰竭患者,分为卡维地洛组40例和比索洛尔组39例,另选20名正常健康人为正常对照组,应用酶联免疫吸附法(ELISA)测定治疗前、治疗后1个月及3个月时的血浆 BNP；心脏超声诊断仪测量同期和6个月时心脏结构和功能。结果：治疗前慢性心力衰竭患者血浆 BNP 水平均高于正常对照组(P＜0.01)；治疗后1个月血浆 BNP 水平较治疗前下降(P＜0.05),3个月时下降更加明显(P＜0.01)。3个月时组间比较有显著性差异(P＜0.05)；两组患者治疗后1 个月左心室舒张末内径、左心室舒张末容积、左心室收缩末容积及左心室射血分数(LVEF)与治疗前比较均无统计学差异(P＞0.05)；3个月及6个月时的上述指标与治疗前相比均有显著性差异(P＜0.05,＜0.01)。两组患者血浆 BNP 水平与同期测定的左心室舒张末内径呈正相关(r=0.51,P＜0.01),与 LVEF 呈负相关((r=-0.43,P＜0.01)。结论：慢性心力衰竭患者血浆 BNP 水平的变化早于心脏超声指标的变化；血浆 BNP 水平可以作为治疗心力衰竭的一个可靠观察指标。
Objective： To observe the changes of plasma level of brain natriuretic peptide（BNP） and left ventficular function in patients with chronic heart failure （CHF）.
Methods： Plasma levels of BNP of 79 CHF patients and 20 healthy subjects were measured with ELISA before, and 1, 3 months after treatment. Constructive and functional parameters were obtained by echocardiography.
Results ： The plasma BNP level in CHF patients were significantly higher than those of the healthy subjects（ P 〈 0. 01 ）. One after treatment, BNP level began to decrease（P 〈 0. 05）, and more significantly 3 months later （P 〈 0.01 ）. The changes of constructive and functional parameters were obserred only after 3-or 6-month treatment（P 〈 0. 05, 〈 0. 01 ）. The plasma BNP level was positivly correlated with LVEDd （ r = 0. 51, P 〈 0. 01 ）, and negativly correlated with LVEF （ r = - 0. 43, P 〈 0.01 ）.
Conclusions： The change of BNP level develops earlier than that of echocardiographic assessment. BNP level can be used as a reliable index for treatment of chronic heart failure.
出处
《中国循环杂志》
CSCD
北大核心
2006年第1期36-38,共3页
Chinese Circulation Journal
关键词
脑钠素
心力衰竭
卡维地洛
比索洛尔
Brain natriuretic peptide
Chronic heart failure
Carvedilol
Bisoprolol
